Ignite Creation Date:
2024-05-06 @ 10:49 AM
Last Modification Date:
2024-10-26 @ 12:36 PM
Study NCT ID:
NCT03362047
Status:
RECRUITING
Last Update Posted:
2024-05-08
First Post:
2017-11-22
Brief Title:
RIGHT HEART III Study - Right Ventricular Hemodynamic Evaluation and Response to Treatment
Sponsor:
University of Giessen
Organization:
University of Giessen
Study Overview
Official Title:
Untersuchung Des Einflusses PAH-spezifischer Medikation Auf Die rechtsventrikuläre Funktion Bei Patienten Mit Pulmonaler Arterieller Hypertonie PAH Unter Basalen Bedingungen
Status:
RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
RightHeartIII
Brief Summary:
Pilot study to determine the therapeutic effect of two prarallel groups treated with either Riciguat or Macitentan evaluated by the change in systolic and diastolic RV function within 12 weeks after first drug intake in order to plan a larger Phase II study
Detailed Description:
In this multi-center randomized open pilot study the therapeutic effect of two prarallel groups treated with either Riciguat or Macitentan shall be determined by evaluating the change in systolic and diastolic RV function within 12 weeks after first drug intake in order to plan a larger Phase II studyThe method used to determine the RV function will be the Conductance Method
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2015-002835-17 | EUDRACT_NUMBER | None | None |